Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
CAMZYOS (MAVACAMTEN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
CAMZYOS
NDA
Get alerts
MAVACAMTEN | N214998 | BRISTOL MYERS SQUIBB CO
4 strengths
2 unique patents
3 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
DMF
Approvals
Label
Products
Patent Timeline
2 unique patents, 3 exclusivities by expiration date
All strengths
2.5MG
5MG
10MG
15MG
Active (2)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
RE50050
Apr. 28, 2036
9585883
Jun. 19, 2034
M-297
Jun. 15, 2026
NCE
Apr. 28, 2027
ODE-398
Apr. 28, 2029
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 2.5MG
RLD
2 patents
3 exclusivities
▴
CAPSULE;ORAL | Approved: Apr 28, 2022
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
RE50050
Apr 28, 2036
—
Yes
Yes
—
—
9585883
Jun 19, 2034
—
—
—
U-3373
TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
—
Exclusivities (3)
Code
Date
Status
M-297
Jun 15, 2026
Expired
NCE
Apr 28, 2027
< 1 year
ODE-398
Apr 28, 2029
Active
#002 — 5MG
RLD
2 patents
3 exclusivities
▾
CAPSULE;ORAL | Approved: Apr 28, 2022
#003 — 10MG
RLD
2 patents
3 exclusivities
▾
CAPSULE;ORAL | Approved: Apr 28, 2022
#004 — 15MG
RLD
2 patents
3 exclusivities
▾
CAPSULE;ORAL | Approved: Apr 28, 2022